Yellow Fever Virus Vaccine Reduces T Cell Receptor Signaling and the Levels of Phosphatase PTPRE In Vivo

<strong>Background:</strong> A Src kinase-activating phosphatase (PTPRE) is targeted by a genome-derived yellow fever virus (YFV) short noncoding RNA (vsRNA) in vitro. The vsRNA reduces PTPRE translation, which leads to reduced TCR signaling. vsRNA point mutations restore PTPRE expressio...

Full description

Bibliographic Details
Main Authors: Jinhua Xiang, James H. McLinden, Qing Chang, Thomas M Kaufman, Judy A. Streit, Jack T. Stapleton
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Proceedings
Subjects:
Online Access:https://www.mdpi.com/2504-3900/50/1/97
_version_ 1797564278913368064
author Jinhua Xiang
James H. McLinden
Qing Chang
Thomas M Kaufman
Judy A. Streit
Jack T. Stapleton
author_facet Jinhua Xiang
James H. McLinden
Qing Chang
Thomas M Kaufman
Judy A. Streit
Jack T. Stapleton
author_sort Jinhua Xiang
collection DOAJ
description <strong>Background:</strong> A Src kinase-activating phosphatase (PTPRE) is targeted by a genome-derived yellow fever virus (YFV) short noncoding RNA (vsRNA) in vitro. The vsRNA reduces PTPRE translation, which leads to reduced TCR signaling. vsRNA point mutations restore PTPRE expression and T cell function. We examined TCR signaling and PTPRE levels in individuals before and after YFV vaccination (YFVax). <b>Methods:</b> Fourteen individuals receiving YFVax (10<sup>4.7–5.6</sup>) IM for travel prophylaxis provided written informed consent for these studies. Blood was obtained once before vaccination and four times after vaccination (days 3 to 28). Serum and PBMCs were purified and YFV was quantified by RNA and infectivity. PBMCs were assessed for activation following anti-CD3 stimulation by measuring phospho-tyrosine-394-Lck and IL-2 release. PBMC PTPRE levels were determined by immunoblot analyses (normalized to actin). A YFV-neutralizing antibody was determined by PRNT. <b>Results:</b> YFVax was administered alone (six out of 14 subjects) or in combination with other vaccines (eight out of 14). All subjects demonstrated reduced resting PBMC PTPRE levels and post-TCR stimulation had reduced IL-2 release between days 4 and 21 compared to pre- and day 28 samples. Phospho-Lck was reduced in all but two subjects on the same days, and both of these subjects also received an influenza vaccine. Low-level viremia was detected in 10/14 subjects, with infectious titers of 100/mL. Viremia was not detected in four out of 14 subjects. All recipients developed neutralizing antibodies by day 21. <b>Conclusion:</b> YFV vaccination regulates PBMC PTPRE levels 4–21 days after infection, despite the low to absent infectious YFV detected in serum, suggesting that enough YFV vsRNA is produced and released from cells to have a functional (and measurable) effect on T cell function. Studies are underway to determine if this is mediated by exosomes or defective particles containing the vsRNA that targets PTPRE. Furthermore, the association between PTPRE and TCR signaling confirms a role for PTPRE in TCR function.
first_indexed 2024-03-10T18:56:08Z
format Article
id doaj.art-34e358a6eb5848c3ab50f355823abbe2
institution Directory Open Access Journal
issn 2504-3900
language English
last_indexed 2024-03-10T18:56:08Z
publishDate 2020-06-01
publisher MDPI AG
record_format Article
series Proceedings
spelling doaj.art-34e358a6eb5848c3ab50f355823abbe22023-11-20T04:46:30ZengMDPI AGProceedings2504-39002020-06-015019710.3390/proceedings2020050097Yellow Fever Virus Vaccine Reduces T Cell Receptor Signaling and the Levels of Phosphatase PTPRE In VivoJinhua Xiang0James H. McLinden1Qing Chang2Thomas M Kaufman3Judy A. Streit4Jack T. Stapleton5Iowa City Veterans Administration HealthCare, The University of Iowa, Iowa City, IA 52242, USAIowa City Veterans Administration HealthCare, The University of Iowa, Iowa City, IA 52242, USAIowa City Veterans Administration HealthCare, The University of Iowa, Iowa City, IA 52242, USAIowa City Veterans Administration HealthCare, The University of Iowa, Iowa City, IA 52242, USAIowa City Veterans Administration HealthCare, The University of Iowa, Iowa City, IA 52242, USAIowa City Veterans Administration HealthCare, The University of Iowa, Iowa City, IA 52242, USA<strong>Background:</strong> A Src kinase-activating phosphatase (PTPRE) is targeted by a genome-derived yellow fever virus (YFV) short noncoding RNA (vsRNA) in vitro. The vsRNA reduces PTPRE translation, which leads to reduced TCR signaling. vsRNA point mutations restore PTPRE expression and T cell function. We examined TCR signaling and PTPRE levels in individuals before and after YFV vaccination (YFVax). <b>Methods:</b> Fourteen individuals receiving YFVax (10<sup>4.7–5.6</sup>) IM for travel prophylaxis provided written informed consent for these studies. Blood was obtained once before vaccination and four times after vaccination (days 3 to 28). Serum and PBMCs were purified and YFV was quantified by RNA and infectivity. PBMCs were assessed for activation following anti-CD3 stimulation by measuring phospho-tyrosine-394-Lck and IL-2 release. PBMC PTPRE levels were determined by immunoblot analyses (normalized to actin). A YFV-neutralizing antibody was determined by PRNT. <b>Results:</b> YFVax was administered alone (six out of 14 subjects) or in combination with other vaccines (eight out of 14). All subjects demonstrated reduced resting PBMC PTPRE levels and post-TCR stimulation had reduced IL-2 release between days 4 and 21 compared to pre- and day 28 samples. Phospho-Lck was reduced in all but two subjects on the same days, and both of these subjects also received an influenza vaccine. Low-level viremia was detected in 10/14 subjects, with infectious titers of 100/mL. Viremia was not detected in four out of 14 subjects. All recipients developed neutralizing antibodies by day 21. <b>Conclusion:</b> YFV vaccination regulates PBMC PTPRE levels 4–21 days after infection, despite the low to absent infectious YFV detected in serum, suggesting that enough YFV vsRNA is produced and released from cells to have a functional (and measurable) effect on T cell function. Studies are underway to determine if this is mediated by exosomes or defective particles containing the vsRNA that targets PTPRE. Furthermore, the association between PTPRE and TCR signaling confirms a role for PTPRE in TCR function.https://www.mdpi.com/2504-3900/50/1/97yellow fever virusrestriction factorPTPREnoncoding RNAyellow fever vaccine
spellingShingle Jinhua Xiang
James H. McLinden
Qing Chang
Thomas M Kaufman
Judy A. Streit
Jack T. Stapleton
Yellow Fever Virus Vaccine Reduces T Cell Receptor Signaling and the Levels of Phosphatase PTPRE In Vivo
Proceedings
yellow fever virus
restriction factor
PTPRE
noncoding RNA
yellow fever vaccine
title Yellow Fever Virus Vaccine Reduces T Cell Receptor Signaling and the Levels of Phosphatase PTPRE In Vivo
title_full Yellow Fever Virus Vaccine Reduces T Cell Receptor Signaling and the Levels of Phosphatase PTPRE In Vivo
title_fullStr Yellow Fever Virus Vaccine Reduces T Cell Receptor Signaling and the Levels of Phosphatase PTPRE In Vivo
title_full_unstemmed Yellow Fever Virus Vaccine Reduces T Cell Receptor Signaling and the Levels of Phosphatase PTPRE In Vivo
title_short Yellow Fever Virus Vaccine Reduces T Cell Receptor Signaling and the Levels of Phosphatase PTPRE In Vivo
title_sort yellow fever virus vaccine reduces t cell receptor signaling and the levels of phosphatase ptpre in vivo
topic yellow fever virus
restriction factor
PTPRE
noncoding RNA
yellow fever vaccine
url https://www.mdpi.com/2504-3900/50/1/97
work_keys_str_mv AT jinhuaxiang yellowfevervirusvaccinereducestcellreceptorsignalingandthelevelsofphosphataseptpreinvivo
AT jameshmclinden yellowfevervirusvaccinereducestcellreceptorsignalingandthelevelsofphosphataseptpreinvivo
AT qingchang yellowfevervirusvaccinereducestcellreceptorsignalingandthelevelsofphosphataseptpreinvivo
AT thomasmkaufman yellowfevervirusvaccinereducestcellreceptorsignalingandthelevelsofphosphataseptpreinvivo
AT judyastreit yellowfevervirusvaccinereducestcellreceptorsignalingandthelevelsofphosphataseptpreinvivo
AT jacktstapleton yellowfevervirusvaccinereducestcellreceptorsignalingandthelevelsofphosphataseptpreinvivo